Article
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Blood - 15 Aug 2007
Tefferi Ayalew, Thiele Juergen, Orazi Attilio, Kvasnicka Hans Michael, Barbui Tiziano, Hanson Curtis A, Barosi Giovanni, Verstovsek Srdan, Birgegard Gunnar, Mesa Ruben, Reilly John T, Gisslinger Heinz, Vannucchi Alessandro M, Cervantes Francisco, Finazzi Guido, Hoffman Ronald, Gilliland D Gary, Bloomfield Clara D, Vardiman James W
Abstract excerpt
The Janus kinase 2 mutation, JAK2617V>F, is myeloid neoplasm-specific; its presence excludes secondary polycythemia, thrombocytosis, or bone marrow fibrosis from other causes. Furthermore, JAK2617V>F or a JAK2 exon 12 mutation is present in virtually all patients with polycythemia vera (PV), whereas JAK2617V>F also occurs in approximately half of patients with essential thrombocythemia (ET) or primary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.